https://www.selleckchem.com/pr....oducts/anlotinib-al3
BRCA1 mutation carriers are recommended to undergo prophylactic risk-reducing salpingo-oophorectomy (RRSO) between the ages of 35 and 40 or when child bearing is complete, with a possible delay until age 40-45 for BRCA2 mutation carriers. Primary outcome was the rate of unsuspected cancer findings during RRSO in a region of northern Italy (Emilia Romagna) and secondary outcomes were details of RRSO age at surgical intervention, the venue of the procedures in relation to the surgical/pathological quality and the rate/role of con
Curtir
Comentario
Compartilhar
